Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer: DNA and RNA Sequencing
Getting access
Committee review Disease-Specific (Cancer) (DS-CA)
- Apply at
- https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003801.v2.p1
- Agreement
- Data use agreement
- Cost
- No charge
- Renewal
- Every 1 year
From the operator’s published policy metadata.
About this database
| Last updated | 2026-09-11 |
|---|